CX3CL1 and polycystic ovary syndrome: Administration of fractalkine did not interfere with the expression pattern of phosphorylated p38 (1.190 ± 0.026 versus 0.986 ± 0.035 for PCOS with fractalkine versus Ctl with fractalkine, respectively, P < 0.05; 0.986 ± 0.035 versus 1.000 ± 0.024 for Ctl with fractalkine versus Ctl, respectively, P = 0.778; 1.190 ± 0.026 versus 1.146 ± 0.015 for PCOS with fractalkine versus PCOS, respectively, P = 0.274; Fig. 4A).